ImmuCell Corporation (ICCC)

US — Healthcare Sector

Peers: TRGNF ACOGF FENC LIPO ELYM CYT ANEB HCWB MNOV AGE LCTX CVKD ONTTF RZLT XOMAO PTIX TPST

Automate Your Wheel Strategy on ICCC

With Tiblio's Option Bot, you can configure your own wheel strategy including ICCC - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

symbol ICCC
Rev/Share 900.4307
Book/Share 3658.9526
PB 0.0021
Debt/Equity 0.2072
CurrentRatio 4.1181
ROIC 0.0124

MktCap 61002450.0
FreeCF/Share 138.5575
PFCF 0.049
PE 0.0419
Debt/Assets 0.1317
DivYield 0
ROE 0.1989

Rating B+
Score 3
Recommendation Neutral
P/E Score 3
DCF Score 1
P/B Score 5
D/E Score 2

Recent Analyst Ratings

Type	Ticker	Analyst Firm	Previous Rating	Current Rating	Previous Price Target	Current Price Target	Date
No ratings available.

News

ImmuCell to Hold Virtual-Only Annual Meeting of Stockholders

ICCC
Published: June 05, 2025 by: GlobeNewsWire
Sentiment: Neutral

PORTLAND, Maine, June 05, 2025 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today announced that its 2025 Annual Meeting of Stockholders (the “Annual Meeting”) will be conducted virtually on Thursday, June 12, 2025, at 9:30 AM ET, as previously disclosed in its Proxy Statement that was filed with the Securities and Exchange Commission (“SEC”) on April 24, 2025.

image for news ImmuCell to Hold Virtual-Only Annual Meeting of Stockholders

ImmuCell Reports Y/Y Q1 Earnings Growth on Record Sales & Margin Gains

ICCC
Published: May 19, 2025 by: Zacks Investment Research
Sentiment: Positive

ICCC posts record Q1 sales, returns to earnings and expands margins y/y as First Defense demand grows and production issues subside.

image for news ImmuCell Reports Y/Y Q1 Earnings Growth on Record Sales & Margin Gains

ImmuCell Corporation (ICCC) Q1 2025 Earnings Call Transcript

ICCC
Published: May 15, 2025 by: Seeking Alpha
Sentiment: Neutral

ImmuCell Corporation (NASDAQ:ICCC ) Q1 2025 Earnings Conference Call May 15, 2025 9:00 AM ET Company Participants Joe Diaz - Managing Partner, Lytham Partners, LLC Michael Brigham - President & Chief Executive Officer Tim Fiori - Chief Financial Officer Conference Call Participants George Melas - MKH Management Russ Tolander - Capital Alliance Operator Good morning and welcome to the ImmuCell Corporation Reports First Quarter Ended March 31st, 2025 Audited Financial Results Conference Call. All participants will be in listen-only mode.

image for news ImmuCell Corporation (ICCC) Q1 2025 Earnings Call Transcript

ImmuCell to Announce Unaudited Financial Results for the Quarter Ended March 31, 2025

ICCC
Published: May 12, 2025 by: GlobeNewsWire
Sentiment: Neutral

PORTLAND, Maine, May 12, 2025 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, expects to report unaudited financial results for the quarter ended March 31, 2025 after the market closes on Wednesday, May 14, 2025. The Company is planning to host a conference call the next morning, Thursday, May 15, 2025, at 9:00 AM ET to review the unaudited financial results.

image for news ImmuCell to Announce Unaudited Financial Results for the Quarter Ended March 31, 2025

ImmuCell Posts Y/Y Q4 Earnings Growth, Awaits FDA Approval for Re-Tain

ICCC
Published: February 28, 2025 by: Zacks Investment Research
Sentiment: Positive

ImmuCell posts 52% y/y sales growth in Q4. It improves margins and eyes FDA approval for Re-Tain to drive expansion.

image for news ImmuCell Posts Y/Y Q4 Earnings Growth, Awaits FDA Approval for Re-Tain

ImmuCell Corporation (ICCC) Q4 2024 Earnings Call Transcript

ICCC
Published: February 26, 2025 by: Seeking Alpha
Sentiment: Neutral

ImmuCell Corporation (NASDAQ:ICCC ) Q4 2024 Earnings Conference Call February 26, 2025 9:00 AM ET Company Participants Joe Diaz - Managing Partner, Lytham Partners, LLC Michael Brigham - President and Chief Executive Officer Conference Call Participants George Melas-Kyriazi - MKH Management Operator Good morning, and welcome to ImmuCell Corporation Reports its Fourth Quarter and Year Ended December 31, 2024, Unaudited Financial Results Conference Call. All participants will be in listen-only mode.

image for news ImmuCell Corporation (ICCC) Q4 2024 Earnings Call Transcript

About ImmuCell Corporation (ICCC)

IPO Date 1987-05-05
Website https://immucell.com
Industry Biotechnology
CEO Mr. Michael F. Brigham
Employees 69

ImmuCell Corporation, an animal health company, develops, manufactures, and markets products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. It offers First Defense, an orally delivered scours preventive product for newborn dairy and beef calves; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus. The company also provides California Mastitis Test that is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is mastitic; and Dual-Force First Defense, including a whey protein concentrate for the nutritional and feed supplement markets. In addition, it is involved in developing Re-Tain, a Nisin-based intramammary treatment of subclinical mastitis in lactating dairy cows. It sells its products through animal health distributors. ImmuCell Corporation was incorporated in 1982 and is headquartered in Portland, Maine.